PSA

(redirected from prostate-specific antigen)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

PSA

See: Public Securities Association.

Security Industry and Financial Markets Association

Formerly known as the Public Securities Association, a professional organization for banks, broker-dealers, and other organizations that underwrite securities. It serves as a lobbying group and provides education and training to members and non-members. It maintains offices in New York, Washington DC, and London, with affiliated offices in Hong Kong and other locations.

Mentioned in ?

References in periodicals archive ?

Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: A large-scale Korean screening study.

Clinicopathological correlation of serum prostate specific antigen levels in patients of prostatomegaly in a tertiary care hospital

Operation characteristics of prostate-specific antigen in men with an initial PSA level of 3.

Prostate cancer screening: Canadian guidelines 2011

Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.

Detection of complexes between prostate-specific antigen and protease inhibitors in plasma

Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a ennui human prostatic serine protease identified by degeneorato PCR.

Total, free and complexed PSA and hK2 for early detection of prostate cancer. (Cover Story)

Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.

Determination of non-[[alpha].sub.1], -antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy

Prostate-specific antigen and its complexes with ai antichymotrypsin in the plasma of patients with prostatic disease.

The proportion of prostate-specific antigen (PSA) complexed to [[alpha].sub.1]-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 [micro]g/L

Growth regulation of prostatic stromal cells by prostate-specific antigen.

Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step

High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen.

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease

Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 [micro]g/I--are they useful tools for early detection and screening of prostate cancer?

Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies

The major form of prostate-specific antigen (PSA) in serum is complexed to [[alpha].

Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer?

Congress' resolution encouraging physicians to inform prostate cancer patients of all proven treatments available and use of prostate-specific antigen (PSA) and mammogram tests for early detection of cancer.

Changes in Reimbursement Structure to Aid Greater Adoption of Brachytherapy

During the past 15 years, the immunochemical detection of prostate-specific antigen (PSA)[7] has become an indispensable prostate cancer (PCa) marker.

Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing